These findings highlight the potential of CXCR4 antagonist therapy as a promising strategy for improving peripheral blood neutropenia and other clinical manifestations in individuals with CXCR2 deficiencies, as well as in various subsets of SCN. This evidence concerns the gene CXCR2 and Decreased total neutrophil count.